Develops gene therapies for genetic diseases.
Jun 2026Revenue $1.97B/yrExpenses $2.12B/yr
No trend
Figures by year
When will Sarepta Therapeutics be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Jun 2026, revenue was $1.97B and expenses $2.12B.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $2.20B | $2.90B | −$700M |
| Dec 2024 | $1.90B | $1.68B | $218M |
| Dec 2023 | $1.24B | $1.51B | −$268M |
| Dec 2022 | $933M | $1.47B | −$536M |
| Dec 2021 | $702M | $1.16B | −$460M |
| Dec 2020 | $540M | $1.10B | −$564M |
| Dec 2019 | $381M | $1.09B | −$706M |
| Dec 2018 | $301M | $645M | −$344M |
| Dec 2017 | $155M | $326M | −$172M |
| Dec 2016 | $5.42M | $272M | −$267M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.